Buy & Sell AST SpaceMobile Inc (ASTS) – AST SpaceMobile Inc Price Today
Aura AI Summary
Key Stats
- $25.94BMarket Cap
- MediaSector
- -39.11%3M Drawdown
- $25.90BEnterprise Value
- -Dividend Yield
- 51% Buy | 49% SellTrading Activity
- 27 daysTypical Hold Time
AST SpaceMobile Inc (ASTS) is currently valued at a market capitalization of $25.94B, with an enterprise value of $25.90B. Over the past 52 weeks, AST SpaceMobile Inc has traded between a low of $23.07 and a high of $122.09, highlighting its annual price range. Over the past three months, AST SpaceMobile Inc has recorded a drawdown of -39.11%, reflecting recent price volatility. On average, investors hold AST SpaceMobile Inc for approximately 27 days, indicating typical investor behavior on the platform.
About AST SpaceMobile Inc
AST SpaceMobile Inc is a satellite designer and manufacturer. The company is building the global cellular broadband network in space to operate directly with standard, unmodified mobile devices based on extensive IP and patent portfolio. AST is on a mission to eliminate the connectivity gaps faced by mobile subscribers and finally bring broadband to the billions who remain unconnected.
Most Recent News
Law firm probes fairness of major energy and tech mergers for shareholders.
Halper Sadeh LLC is investigating whether shareholders of LiveRamp, Dominion Energy, Sachem Capital, and NextEra Energy are receiving fair deals in their companies' recent mergers and acquisitions. The firm suspects insiders may gain financial benefi...

Bill Ackman's sale of Alphabet shares cost $641M; Microsoft bet offsets some losses but not all.
In Q1 2026, Bill Ackman sold 95% of his Alphabet shares, missing out on $641 million in gains as the stock surged. He shifted his investment to Microsoft, which gained $271.8 million since the end of the quarter, partially offsetting the losses. Ackm...

Law firm investigates InMed Pharmaceuticals' board over possible unfair sale to Mentari Therapeutics
Brodsky & Smith LLC is investigating claims against the Board of Directors of InMed Pharmaceuticals regarding potential breaches of fiduciary duty in the company's sale to Mentari Therapeutics. The investigation questions whether the board conducted ...
